SECsense Logo

Entrada Therapeutics 8-K Report: Key Insights & Filing Date January 15, 2025

$TRDA
Form 8-K
Filed on: 2025-01-15
Source
Entrada Therapeutics 8-K Report: Key Insights & Filing Date January 15, 2025

Based on the provided XML section of the financial report, here are the key insights and important information extracted:

  1. Company Information:
  • Name: Entrada Therapeutics, Inc.
  • CIK Number: 0001689375
  • Address: One Design Center Place, Suite 17-500, Boston, MA 02210
  • Phone: 857-520-9158
  • Stock Ticker: TRDA (traded on NASDAQ)
  1. Filing Details:
  • Form Type: 8-K (a report of unscheduled material events or corporate changes)
  • Filing Date: January 15, 2025
  1. Stock Information:
  • Common Stock: Par value of $0.0001 per share.
  1. Reporting Period:
  • As Of Date: January 15, 2025 (the reporting date is the same as the filing date)
  1. Units of Measurement:
  • Currency: USD (U.S. Dollars)
  • Shares: The filing mentions shares, but the specific number of shares or any financial metrics related to shares is not provided in this excerpt.
  1. Regulatory Framework:
  • The filing adheres to XBRL (eXtensible Business Reporting Language) standards, which is used by the SEC for financial reporting.

This information highlights that Entrada Therapeutics filed an 8-K report on January 15, 2025, providing insights into company details and stock specifics but lacks detailed financial metrics in the provided excerpt.